<DOC>
	<DOCNO>NCT02679456</DOCNO>
	<brief_summary>This randomize , multicenter , evaluator blind study evaluate safety , tolerability , efficacy pharmacokinetics SCY-078 compare Fluconazole adult patient moderate severe Vulvovaginal Candidiasis ( VVC ) history frequent episode VVC . Approximately 90 subject , meet inclusion criterion enrol randomized 1:1:1 ratio one 3 treatment arm : Oral SCY-078 2 dose regimen oral Fluconazole . After enrollment , subject evaluate Day-5 ( end treatment visit ) , Day-24 ( test cure visit ) , Day-60 , Day 90 Day 120 ( end observation period visit ) time recurrence clinical failure suspect , end observation period .</brief_summary>
	<brief_title>Safety Efficacy Oral SCY-078 v . Oral Fluconazole Subjects With Vulvovaginal Candidiasis</brief_title>
	<detailed_description>This randomize , multicenter , evaluator blind study evaluate safety , tolerability , efficacy pharmacokinetics SCY-078 compare Fluconazole adult patient , 18 65 year age , moderate severe Vulvovaginal Candidiasis ( VVC ) history frequent episode VVC . Approximately 90 subject , meet inclusion criterion enrol randomized 1:1:1 ratio one 3 treatment arm : oral SCY-078 regimen 1 , oral SCY-078 regimen 2 , oral Fluconazole . After enrollment , subject evaluate Day-5 ( end treatment visit ) , Day-24 ( test cure visit ) , Day-60 , Day 90 Day 120 ( end observation period visit ) time recurrence clinical failure suspect , end observation period . Primary Objectives : * To evaluate safety efficacy 2 dosing regimen Oral SCY-078 subject moderate severe Vulvovaginal Candidiasis ( VVC ) Secondary Objectives : * To estimate effect Oral SCY-078 therapy rate time recurrence subject history frequent episode VVC</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Subjects must fulfill follow criterion eligible study admission : 1 . Female subject 18 65 year age good general health 2 . Diagnosis symptomatic moderate severe vulvovaginal candidiasis 3 . The ability understand sign write informed consent form ( ICF ) , must obtain prior treatment studyrelated procedure . 4 . The ability understand sign consent authorization form shall permit use , disclosure transfer subject 's personal health information ( e.g. , U.S. HIPAA Authorization form ) . 5 . The ability understand follow studyrelated procedure include study drug administration . 6 . Females childbearing potential must agree use medically acceptable method contraception receive protocolassigned product . A subject exclude participation study meet follow exclusion criterion : 1 . Any vaginal condition VVC may interfere diagnosis evaluation response therapy . 2 . Prior use prohibit medication ( ) procedure ( ) within protocol specify timeframe include : . Systemic and/or topical ( vaginal ) antifungal treatment , prescription counter , within 30 day baseline visit . 3 . Subjects history renal impairment , hepatic impairment cervical cancer . 4 Subjects know hypersensitivity enfumafungin derivative , fluconazole component formulation . 5 . HIV infection , chemotherapy illness serious enough induce immune deficiency .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>